Company profile
Adlai Nortye Group Ltd.
NASDAQ:ANLBiotechnology: Pharmaceutical Preparations
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07686445 | phase1 | not_yet_recruiting | 2026-09-23 | 2028-12-31 | Adlai Nortye Biopharma Co., Ltd. | A Study of AN4035 in Advanced Cancers With RAS Mutations and High CEACAM5 Expression |
| NCT05191667 | phase1 | suspended | 2022-01-18 | 2025-12-01 | Adlai Nortye Biopharma Co., Ltd. | AN0025 and Chemoradiotherapy Combination in Esophageal Cancer |
| NCT04432857 | phase1 | unknown | 2020-08-20 | 2024-05-31 | Adlai Nortye Biopharma Co., Ltd. | AN0025 and Pembrolizumab Combination in Advanced Solid Tumors |
| NCT07639047 | phase1 | recruiting | 2025-11-01 | 2027-07-01 | Adlai Nortye Biopharma Co., Ltd. | An Initial Evaluation of AN8025 in Solid Tumors |
| NCT04975958 | phase1 | completed | 2021-09-07 | 2025-01-24 | Adlai Nortye Biopharma Co., Ltd. | Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors |
FDA applications (0)
No records yet.